Agency Information Collection Activities: Proposed Collection; Comment Request, 45407-45408 [05-15500]
Download as PDF
Federal Register / Vol. 70, No. 150 / Friday, August 5, 2005 / Notices
ACTION:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Targeting
Technologies.
Date: August 5, 2005.
Time: 1 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Steven J. Jullo, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4192,
MSC 7849, Bethesda, MD 20892, (301) 435–
2810, zullost@scr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: August 1, 2005.
Anthony M. Coelho, Jr.,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–15538 Filed 8–4–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Development and Use of
Cripto-1 as a Biomarker and Treatment
for Neurodegenerative Disease
National Institutes of Health,
Public Health Service, HHS.
AGENCY:
VerDate jul<14>2003
15:34 Aug 04, 2005
Jkt 205001
Notice.
SUMMARY: This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), that the National
Institutes of Health, Department of
Health and Human Services, is
contemplating the grant of an exclusive
patent license to practice the inventions
embodied in U.S. Patent Application
60/508,750, filed October 3, 2003
[DHHS Ref. E–075–2003/0–US–01] and
PCT Application PCT/US04/32649
[DHHS Ref. E–075–2003/0–PCT–02],
entitled Use of Cripto-1 as a Biomarker
for Neurodegenerative Disease and
Method of Inhibiting Progression
Thereof, to Neuronascent, Inc., which is
located in Clarksville, Maryland. The
patent rights in these inventions have
been assigned to the United States of
America.
The prospective exclusive license
territory may be worldwide and the
field of use may be limited to the
development and use of Cripto small
molecule inhibitors to treat and prevent
Alzheimer’s disease in humans.
DATES: Only written comments and/or
applications for a license, which are
received by the NIH Office of
Technology Transfer on or before
October 4, 2005 will be considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, comments,
and other materials relating to the
contemplated exclusive license should
be directed to: Michelle A. Booden,
Ph.D., Technology Licensing Specialist,
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, MD
20852–3804; telephone: (301) 451–7337;
Facsimile: (301) 402–0220; e-mail:
boodenm@mail.nih.gov.
The
technology relates to another use of
Cripto-1 as a biomarker and possible
therapeutic target for a variety of
neurodegenerative diseases, including
NeuroAids, Alzheimer’s disease,
Multiple Sclerosis, Amyotrophic Lateral
Sclerosis, Parkinson’s disease and
encephalitis. Cripto-1 appears to be
overexpressed by 20-fold or more in
NeuroAids and as such, may be
enhanced in other inflammatory
neurological diseases, and thus assist in
the early detection of neurological
changes associated with these diseases,
as well as a possible therapeutic target
for slowing progression.
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7. The prospective
exclusive license may be granted unless
within sixty (60) days from the date of
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
45407
this published notice, the NIH receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR 404.7.
Applications for a license in the field
of use filed in response to this notice
will be treated as objections to the grant
of the contemplated exclusive license.
Comments and objections submitted to
this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: July 28, 2005.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 05–15540 Filed 8–4–05; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Proposed Collection;
Comment Request
In compliance with section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 concerning
opportunity for public comment on
proposed collections of information, the
Substance Abuse and Mental Health
Services Administration (SAMHSA)
will publish periodic summaries of
proposed projects. To request more
information on the proposed projects or
to obtain a copy of the information
collection plans, call the SAMHSA
Reports Clearance Officer on (240) 276–
1243.
Comments are invited on: (a) Whether
the proposed collections of information
are necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(b) the accuracy of the agency’s estimate
of the burden of the proposed collection
of information; (c) ways to enhance the
quality, utility, and clarity of the
information to be collected; and (d)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques or
other forms of information technology.
E:\FR\FM\05AUN1.SGM
05AUN1
45408
Federal Register / Vol. 70, No. 150 / Friday, August 5, 2005 / Notices
Proposed Project: Notification of Intent
To Use Schedule III, IV, or V Opioid
Drugs for the Maintenance and
Detoxification Treatment of Opiate
Addiction Under 21 U.S.C. 823(g)(2)
(OMB No. 0930–0234)—Revision
The Drug Addiction Treatment Act of
2000 (‘‘DATA,’’ Pub. L. 106–310)
amended the Controlled Substances Act
(21 U.S.C. 823(g)(2)) to permit
practitioners (physicians) to seek and
obtain waivers to prescribe certain
approved narcotic treatment drugs for
the treatment of opiate addiction. The
legislation sets eligibility requirements
and certification requirements as well as
an interagency notification review
process for physicians who seek
waivers.
To implement these new provisions,
SAMHSA developed a notification form
(SMA–167) that facilitates the
submission and review of notifications.
The form provides the information
necessary to determine whether
practitioners (i.e., independent
physicians and physicians in group
practices (as defined under section
1877(h)(4) of the Social Security Act)
meet the qualifications for waivers set
forth under the new law. Use of this
form will enable physicians to know
they have provided all information
needed to determine whether
practitioners are eligible for a waiver.
However, there is no prohibition on
use of other means to provide requisite
information. The Secretary will convey
notification information and
determinations to the Drug Enforcement
Administration (DEA), which will
assign an identification number to
qualifying practitioners; this number
will be included in the practitioner’s
registration under 21 U.S.C. 823(f).
Practitioners may use the form for two
types of notification: (a) New, and (b)
immediate. Under ‘‘new’’ notifications,
practitioners may make their initial
waiver requests to SAMHSA.
‘‘Immediate’’ notifications inform
SAMHSA and the Attorney General of a
practitioner’s intent to prescribe
immediately to facilitate the treatment
of an individual (one) patient under 21
U.S.C. 823(g)(2)(E)(ii).
The form collects data on the
following items: Practitioner name; state
medical license number and DEA
registration number; address of primary
location, telephone and fax numbers; email address; name and address of
group practice; group practice employer
identification number; names and DEA
registration numbers of group
practitioners; purpose of notification
new, immediate, or renewal;
Number of
respondents
Purpose of submission
certification of qualifying criteria for
treatment and management of opiate
dependent patients; certification of
capacity to refer patients for appropriate
counseling and other appropriate
ancillary services; certification of
maximum patient load, certification to
use only those drug products that meet
the criteria in the law. The form also
notifies practitioners of Privacy Act
considerations, and permits
practitioners to expressly consent to
disclose limited information to the
SAMHSA Buprenorphine Physician
Locator.
Since July 2002, SAMHSA has
received just over 6,000 notifications
and has certified over 5,500 physicians.
Eighty-one percent of the notifications
were submitted by mail or by facsimile,
with approximately twenty percent
submitted through the Web based online
system. Approximately 60 percent of the
certified physicians have consented to
disclosure on the SAMHSA
Buprenorphine Physician Locator.
Respondents may submit the form
electronically, through a dedicated Web
page that SAMHSA will establish for the
purpose, as well as via U.S. mail.
The following table summarizes the
estimated annual burden for the use of
this form.
Responses
per
respondent
Burden per
response
(hr)
Total burden
(hrs)
Initial Application for Waiver ............................................................................
Notification to Prescribe Immediately ..............................................................
2,000
50
1
1
.083
.083
166
4
Total ..........................................................................................................
2,050
........................
........................
170
Send comments to Summer King,
SAMHSA Reports Clearance Officer,
Room 7–1044, One Choke Cherry Road,
Rockville, MD 20857. Written comments
should be received within 60 days of
this notice.
Dated: July 29, 2005.
Anna Marsh,
Executive Officer, SAMHSA.
[FR Doc. 05–15500 Filed 8–4–05; 8:45 am]
BILLING CODE 4162–20–P
DEPARTMENT OF HOMELAND
SECURITY
Office of the Secretary
Public Workshop: Privacy and
Technology: Government Use of
Commercial Data for Homeland
Security
Privacy Office, Department of
Homeland Security.
ACTION: Notice announcing public
workshop.
AGENCY:
SUMMARY: The Department of Homeland
Security Privacy Office will host a
public workshop, ‘‘Privacy and
Technology: Government Use of
Commercial Data for Homeland
Security,’’ to explore the policy, legal,
and technology issues associated with
the government’s use of personally
identifiable commercial data in
protecting the homeland.
VerDate jul<14>2003
15:34 Aug 04, 2005
Jkt 205001
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
The workshop will be held on
September 8, 2005, from 8 a.m. to 4:30
p.m. and on September 9, 2005, from
8:30 a.m. to 12:30 p.m.
ADDRESSES: The Privacy and
Technology Workshop will be held in
the auditorium at the DHS Offices at the
GSA Regional Headquarters Building
located at 7th and D Streets, SW.,
Washington, DC 20024.
FOR FURTHER INFORMATION CONTACT:
Toby Milgrom Levin, Robyn Kaplan,
Kenneth Mortensen, or Peter Sand at
Privacy Workshop, Privacy Office,
Department of Homeland Security,
Arlington, VA 22202, by telephone 571–
227–3813, by facsimile 571–227–4171,
or by e-mail at
privacyworkshop@dhs.gov.
DATES:
SUPPLEMENTARY INFORMATION:
Workshop Goals
The Department of Homeland
Security (DHS) Privacy Office is holding
E:\FR\FM\05AUN1.SGM
05AUN1
Agencies
[Federal Register Volume 70, Number 150 (Friday, August 5, 2005)]
[Notices]
[Pages 45407-45408]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-15500]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Agency Information Collection Activities: Proposed Collection;
Comment Request
In compliance with section 3506(c)(2)(A) of the Paperwork Reduction
Act of 1995 concerning opportunity for public comment on proposed
collections of information, the Substance Abuse and Mental Health
Services Administration (SAMHSA) will publish periodic summaries of
proposed projects. To request more information on the proposed projects
or to obtain a copy of the information collection plans, call the
SAMHSA Reports Clearance Officer on (240) 276-1243.
Comments are invited on: (a) Whether the proposed collections of
information are necessary for the proper performance of the functions
of the agency, including whether the information shall have practical
utility; (b) the accuracy of the agency's estimate of the burden of the
proposed collection of information; (c) ways to enhance the quality,
utility, and clarity of the information to be collected; and (d) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques or other
forms of information technology.
[[Page 45408]]
Proposed Project: Notification of Intent To Use Schedule III, IV, or V
Opioid Drugs for the Maintenance and Detoxification Treatment of Opiate
Addiction Under 21 U.S.C. 823(g)(2) (OMB No. 0930-0234)--Revision
The Drug Addiction Treatment Act of 2000 (``DATA,'' Pub. L. 106-
310) amended the Controlled Substances Act (21 U.S.C. 823(g)(2)) to
permit practitioners (physicians) to seek and obtain waivers to
prescribe certain approved narcotic treatment drugs for the treatment
of opiate addiction. The legislation sets eligibility requirements and
certification requirements as well as an interagency notification
review process for physicians who seek waivers.
To implement these new provisions, SAMHSA developed a notification
form (SMA-167) that facilitates the submission and review of
notifications. The form provides the information necessary to determine
whether practitioners (i.e., independent physicians and physicians in
group practices (as defined under section 1877(h)(4) of the Social
Security Act) meet the qualifications for waivers set forth under the
new law. Use of this form will enable physicians to know they have
provided all information needed to determine whether practitioners are
eligible for a waiver.
However, there is no prohibition on use of other means to provide
requisite information. The Secretary will convey notification
information and determinations to the Drug Enforcement Administration
(DEA), which will assign an identification number to qualifying
practitioners; this number will be included in the practitioner's
registration under 21 U.S.C. 823(f).
Practitioners may use the form for two types of notification: (a)
New, and (b) immediate. Under ``new'' notifications, practitioners may
make their initial waiver requests to SAMHSA. ``Immediate''
notifications inform SAMHSA and the Attorney General of a
practitioner's intent to prescribe immediately to facilitate the
treatment of an individual (one) patient under 21 U.S.C.
823(g)(2)(E)(ii).
The form collects data on the following items: Practitioner name;
state medical license number and DEA registration number; address of
primary location, telephone and fax numbers; e-mail address; name and
address of group practice; group practice employer identification
number; names and DEA registration numbers of group practitioners;
purpose of notification new, immediate, or renewal; certification of
qualifying criteria for treatment and management of opiate dependent
patients; certification of capacity to refer patients for appropriate
counseling and other appropriate ancillary services; certification of
maximum patient load, certification to use only those drug products
that meet the criteria in the law. The form also notifies practitioners
of Privacy Act considerations, and permits practitioners to expressly
consent to disclose limited information to the SAMHSA Buprenorphine
Physician Locator.
Since July 2002, SAMHSA has received just over 6,000 notifications
and has certified over 5,500 physicians. Eighty-one percent of the
notifications were submitted by mail or by facsimile, with
approximately twenty percent submitted through the Web based online
system. Approximately 60 percent of the certified physicians have
consented to disclosure on the SAMHSA Buprenorphine Physician Locator.
Respondents may submit the form electronically, through a dedicated
Web page that SAMHSA will establish for the purpose, as well as via
U.S. mail.
The following table summarizes the estimated annual burden for the
use of this form.
----------------------------------------------------------------------------------------------------------------
Number of Responses per Burden per Total burden
Purpose of submission respondents respondent response (hr) (hrs)
----------------------------------------------------------------------------------------------------------------
Initial Application for Waiver.................. 2,000 1 .083 166
Notification to Prescribe Immediately........... 50 1 .083 4
-----------------
Total....................................... 2,050 .............. .............. 170
----------------------------------------------------------------------------------------------------------------
Send comments to Summer King, SAMHSA Reports Clearance Officer,
Room 7-1044, One Choke Cherry Road, Rockville, MD 20857. Written
comments should be received within 60 days of this notice.
Dated: July 29, 2005.
Anna Marsh,
Executive Officer, SAMHSA.
[FR Doc. 05-15500 Filed 8-4-05; 8:45 am]
BILLING CODE 4162-20-P